RU-58841: The Topical DHT Blocker That Never Made It to Market
Last updated: April 2026
RU-58841 is a non-steroidal androgen receptor antagonist developed by Roussel Uclaf in the 1990s. Topically applied, it blocks DHT from binding to scalp follicle receptors without reducing systemic testosterone — the theoretical holy grail for treating male pattern baldness without sexual side effects. It was abandoned commercially, but never forgotten.
🧪 Buy Ru 58841 Guide at Swiss Chems →Systemic use causes major hormonal disruption
Unlike finasteride — preserves testosterone levels
Research chemical — never commercialized
📋 On this page
How RU-58841 Blocks Hair Loss
Male pattern baldness is driven by DHT binding to androgen receptors in scalp follicles, triggering miniaturization. RU-58841 blocks this at the receptor level — without affecting systemic androgen levels.
RU-58841 is a competitive antagonist at the androgen receptor (AR). It has high affinity for AR but doesn't activate it — it simply occupies the receptor, preventing DHT (and testosterone) from binding. In scalp follicles, this blocks the miniaturization signal. Ki values show strong AR binding comparable to other approved anti-androgens.
The key claimed advantage: after topical application, RU-58841 is rapidly metabolized in skin to an inactive form before reaching systemic circulation. Animal studies showed minimal systemic anti-androgenic effects at doses that achieved scalp AR saturation. This predicts topical specificity — but human PK data is limited and vehicle formulation affects absorption significantly.
Unlike finasteride (which reduces systemic DHT by ~70% via 5-alpha reductase inhibition), RU-58841 doesn't change DHT levels — it blocks the receptor. This means testosterone and DHT blood levels remain normal. The theoretical outcome: hair retention without reduced libido, sexual function, or the mood effects some finasteride users report (post-finasteride syndrome).
RU-58841 is chemically unstable, particularly in solution with propylene glycol/ethanol vehicles. It degrades over weeks to months depending on storage temperature. Community users report significant variability in effectiveness, partly attributable to purchasing or preparing degraded product. Pre-dissolved solutions should be refrigerated and have a limited shelf life.
RU-58841 vs Finasteride vs Minoxidil
The three main tools for androgenetic alopecia — how they compare on mechanism, evidence, and risk.
| Factor | RU-58841 | Finasteride | Minoxidil |
|---|---|---|---|
| Mechanism | AR antagonist (topical) | 5α-reductase inhibitor | Vasodilator / K+ channel |
| Systemic DHT effect | None (theoretically) | ↓70% systemic DHT | None |
| Route | Topical scalp only | Oral (1mg/day) | Topical or oral |
| FDA approval | None — research only | Approved (Propecia) | Approved (Rogaine) |
| Human trial evidence | Limited (P&G studies) | Extensive (decades) | Extensive (decades) |
| Sexual side effects | Low theoretical risk | ~2-5% in trials | Minimal |
| Stability | Poor — degrades in solution | Stable tablet | Stable solution |
| Cost | High (research chem) | Low (generic available) | Low (OTC) |
What Research Shows
Evidence strength by research context. Most published data is preclinical; limited human data exists from Proctor & Gamble studies conducted in the 1990s.
Side Effects & Safety Concerns
Reported from community use and limited animal/human study data. Topical route significantly reduces systemic risk — but doesn't eliminate it.
Key Takeaways
- Potent AR antagonist with confirmed binding affinity in vitro
- Stump-tailed macaque studies showed significant hair regrowth vs vehicle
- Topical metabolism theoretically limits systemic activity
- No systemic DHT reduction — preserves testosterone and DHT blood levels
- Chemical instability is a documented limitation — degrades in solution over time
- No published Phase 3 human efficacy trials — P&G studies were not fully disclosed
- Long-term safety in humans (5+ years) is completely unestablished
- Optimal vehicle formulation for stability and absorption is unknown
- True systemic absorption rate varies significantly by vehicle and skin barrier
- Why Roussel Uclaf/P&G abandoned development — this is speculated, not confirmed
Related Guides
🔬 Research-Grade Peptides
Swiss Chems
Third-party HPLC tested with published COAs. One of the most established research peptide vendors.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost
Evidence-Backed Hair Support
Supplements with actual clinical evidence for hair health — useful alongside or instead of research chemicals for lower-risk protocols.
RU-58841 is not approved for human use. This content is educational only. Use of unapproved research chemicals carries unknown risks. Consult a dermatologist or physician for evidence-based hair loss treatment. HighPeptides does not recommend self-administration of research chemicals.